Colon cancer blood test offers new screening option
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles
US overdose deaths dropped in 2023, the first time since 2018
NEW YORK (AP) — The number of U.S. fatal overdoses fell last year, according to Centers for Disease2024-05-21Canada, Germany sign MOU to implement transatlantic hydrogen corridor
OTTAWA, March 18 (Xinhua) -- Canada and Germany on Monday signed a Memorandum of Understanding (MOU)2024-05-21Trump wins Idaho's Republican presidential caucus
WASHINGTON, March 2 (Xinhua) -- Former U.S. President Donald Trump on Saturday won Idaho's Republica2024-05-21How major US stock indexes fared Wednesday, 4/17/2024
Sinking technology stocks sent Wall Street lower again, and the S&P 500 fell to its fourth strai2024-05-21Target to lower prices on basic goods in response to inflation
Target plans to cut prices on thousands of consumer basics this summer, from diapers to milk, as inf2024-05-21Hong Kong arrests 291 for endangering national security in past 4 years — Radio Free Asia
Hong Kong has arrested 291 people for endangering national security in the near four years since the2024-05-21
atest comment